Methylergonovine

Contraindications

(All not necessarily unanimous): Hypertension, heart disease, toxemia, pregnancy, hypersensitivity, mitral valve stenosis, prolonged use

Cases of threatened spontaneous abortion

Avoid during breastfeeding

Cautions

Second or third stage of labor prior to placenta delivery: complications such as captivation of placenta may occur; avoid accidental injection to newborn babies

Increased risk of myocardial ischemia and infarction with coronary artery disease or risk factors for coronary artery disease

Sepsis, hepatic impairment, renal impairment, peripheral vascular disease

Prolonged use may cause pleuropulmonary, cardiac or retroperitoneal fibrosis

Methylergonovine injection is given into a muscle or into a vein through an IV. You will receive this injection while you are in the delivery room and for a short time after your baby is born, if needed.

Methylergonovine oral is a tablet taken by mouth 3 or 4 times daily for up to 1 week after your baby is born.

Follow all directions on your prescription label. Do not take this medicine in larger or smaller amounts or for longer than recommended.

Methylergonovine should not be used for longer than 1 week unless your doctor has told you otherwise.

Store at room temperature away from moisture, heat, and light.

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

Overdose symptoms may include vomiting, stomach pain, throbbing headache, numbness or tingling in your fingers or toes, cold feeling, weak or shallow breathing, or seizure (convulsions).

Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.

Methylergonovine is used to prevent and control bleeding from the uterus that can happen after childbirth. It belongs to the class of medicines called ergot alkaloids. methylergonovine works by acting directly on the smooth muscles of the uterus and prevents bleeding after giving birth.

methylergonovine is available only with your doctor's prescription.

• Methylergometrine Maleate
• Methylergonovine Maleate

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Solution, Injection, as maleate:

Generic: 0.2 mg/mL (1 mL)

Solution, Injection, as maleate [preservative free]:

Generic: 0.2 mg/mL (1 mL)

Tablet, Oral, as maleate:

Methergine: 0.2 mg [contains methylparaben, propylparaben]

Generic: 0.2 mg [DSC]

• Ergot Derivative

Prevention of hemorrhage:

Oral: 0.2 mg 3 to 4 times daily in the puerperium for up to 7 days (maximum duration: 1 week)

IM, IV: 0.2 mg after delivery of anterior shoulder, after delivery of placenta, or during puerperium; may be repeated every 2 to 4 hours as needed. Note: IV administration should only be considered during life-threatening situations.

• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)

• Patient may experience abdominal pain, nausea, vomiting, or diarrhea. Have patient report immediately to prescriber signs of severe cerebrovascular disease (change in strength on one side is greater than the other, trouble speaking or thinking, change in balance, or change in eyesight), angina, arrhythmia, severe dizziness, passing out, shortness of breath, severe headache, vision changes, hematuria, seizures, hallucinations, leg cramps, tinnitus, or sweating a lot (HCAHPS).

• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.

Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating and advising patients.